Efficacy and Safety of Short Course Therapy With Peginterferon Alpha-2b (PEG-IFN Alfa-2b) and Ribavirin (RBV) for Chronic Hepatitis C (Genotype 4) Participants Achieving a Rapid Virological Response at Week 4 of Treatment (MK-8908B-059)
Clinical trial NCT01606800 · TERMINATED
Trial details
- NCT number
- NCT01606800
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- TERMINATED
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2013-01-01
- Primary completion
- 2015-01-26
- Enrollment
- 45
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.